Management of varices in cirrhosis

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 5, 2011, Pages 721-735

  Thalheimer, Ulrich ^a   Triantos, Christos ^b   Goulis, John ^c   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

banding ligation; cirrhosis; portal hypertension; varices

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCRILATE; CARVEDILOL; CEFTRIAXONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENBUCRILATE; ETHANOLAMINE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NADOLOL; NITRIC ACID DERIVATIVE; NORFLOXACIN; OCTREOTIDE; PLACEBO; PRAZOSIN; PROPRANOLOL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SOMATOSTATIN; SPIRONOLACTONE; SUCRALFATE; TERLIPRESSIN; TIMOLOL; TISSUE ADHESIVE; UNINDEXED DRUG; VAPREOTIDE; VASOACTIVE AGENT; VASOPRESSIN;

ABSCESS; ACUTE DISEASE; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; BLEEDING DISORDER; BRAIN DISEASE; BRAIN EMBOLISM; CHRONIC DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; EARLY INTERVENTION; ENDOSCOPIC SCLEROTHERAPY; ENDOSCOPIC SURGERY; ESOPHAGUS STRICTURE; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FLUID RESUSCITATION; GASTRITIS; HEADACHE; HEPATIC ENCEPHALOPATHY; HUMAN; HYPOTENSION; IATROGENIC DISEASE; IN-STENT RESTENOSIS; INFECTION PREVENTION; INTERMETHOD COMPARISON; LIVER CIRRHOSIS; MAINTENANCE THERAPY; NONHUMAN; PATIENT REFERRAL; PEPTIC ULCER BLEEDING; PORTAL HYPERTENSION; POSTOPERATIVE COMPLICATION; PRIMARY PREVENTION; RECANALIZATION; RETROSTERNAL PAIN; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; SPLEEN DISEASE; STOMACH HEMORRHAGE; STOMACH VARICES; SYSTEMIC DISEASE; SYSTEMIC THERAPY; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VARICOSIS; VASOCONSTRICTION; VEIN LIGATION;

ACUTE DISEASE; HUMANS; LIVER CIRRHOSIS; VARICOSE VEINS;

EID: 79952592390     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.537258     Document Type: Review

References (209)

1. Sherlock S, Dooley J. Diseases of the liver and biliary system. 11th edition. Oxford: Blackwell; 2002
2. Garcia-Tsao G, Groszmann RJ, Fisher RL, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-24 (Pubitemid 15065948)
3. Viallet A, Marleau D, Huet M, et al. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology 1975;69:1297-300
4. Zoli M, Berzigotti A. Natural history of formation and growth of oesophageal varices. In: de Franchis R, editor. Portal hypertension IV: proceedings of the Fourth Baveno International Consensus Workshop on methodology of diagnosis and treatment. Oxford: Blackwell; 2006. p. 118-22
5. Giannini EG, Zaman A, Kreil A, et al. Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. Am J Gastroenterol 2006;101:2511-19 (Pubitemid 44665246)
6. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. Portal hypertension and gastrointestinal bleeding. Semin Liver Dis 2008;28:3-25 (Pubitemid 351326530)
7. Chalasani N, Kahi C, Francois F, et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol 2003;98:653-9 (Pubitemid 36348540)
8. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988;319:983-9
9. Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999;353:139-42 (Pubitemid 29088094)
10. Thalheimer U, Triantos CK, Samonakis DN, et al. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005;54:556-63 (Pubitemid 40395508)
11. Feu F, Bordas JM, Garcia-Pagan JC, et al. Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension. Hepatology 1991;13:917-22
12. Cales P, Oberti F, Payen JL, et al. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. Eur J Gastroenterol Hepatol 1999;11:741-5 (Pubitemid 29349018)
13. Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterol 2004;127(2):476-84 (Pubitemid 39091896)
14. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-61 (Pubitemid 41697288)
15. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-76 (Pubitemid 40805288)
16. Perez-Ayuso RM, Pique JM, Bosch J, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 1991;337:1431-4
17. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. J Hepatol 1989;9:75-83
18. The PROVA Study Group. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. Hepatology 1991;14:1016-24
19. Andreani T, Poupon RE, Balkau BJ, et al. Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology 1990;12:1413-19
20. Colman J, Jones P, Finch C, Dudley F. Propranolol in the prevention of variceal hemorrhage in alcoholic cirrhotic patients [abstract]. Hepatology 1990;12:851
21. Conn HO, Grace ND, Bosch J, et al.; Boston-New Haven-Barcelona Portal Hypertension Study Group. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: a multicenter, randomized clinical trial. Hepatology 1991;13:902-12
22. Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987;317:856-61 (Pubitemid 17160539)
23. Strauss E, Desa MG, Albano A, et al. A randomized controlled trial for the prevention of the 1st upper gastrointestinal bleeding due to portal hypertension in cirrhosis-sclerotherapy or propranolol versus cintrol groups [abstract]. Hepatology 1988;8:1395
24. Ideo G, Bellati G, Fesce E, Grimoldi D. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. Hepatology 1988;8:6-9 (Pubitemid 18092050)
25. Lebrec D, Poynard T, Capron JP, et al. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. J Hepatol 1988;7:118-25
26. Poynard T, Cales P, Pasta L, et al.; Franco-Italian Multicenter Study Group. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Engl J Med 1991;324:1532-8
27. Abraczinskas DR, Ookubo R, Grace ND, et al. Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? Hepatology 2001;34:1096-102 (Pubitemid 33100012)
28. Merkel C, Marin R, Enzo E, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP). Lancet 1996;348:1677-81 (Pubitemid 27007529)
29. Merkel C, Marin R, Sacerdoti D, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000;31:324-9 (Pubitemid 30078595)
30. Garcia-Pagan JC, Morillas R, Banares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology 2003;37:1260-6 (Pubitemid 36667304)
31. Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. Aliment Pharmacol Ther 2010;32:859-71
32. Piai G, Cipolletta L, Claar M, et al. Prophylactic sclerotherapy of high-risk esophageal varices: results of a multicentric prospective controlled trial. Hepatology 1988;8:1495-500 (Pubitemid 19021878)
33. Potzi R, Bauer P, Reichel W, et al. Prophylactic endoscopic sclerotherapy of oesophageal varices in liver cirrhosis. A multicentre prospective controlled randomised trial in Vienna. Gut 1989;30:873-9 (Pubitemid 19167793)
34. Witzel L, Wolbergs E, Merki H. Prophylactic endoscopic sclerotherapy of oesophageal varices. A prospective controlledstudy. Lancet 1985;1:773-5 (Pubitemid 15111937)
35. Pagliaro L, D'Amico G, Sorensen TI, et al. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med 1992;117:59-70
36. The Veterans Affairs Cooperative Variceal Sclerotherapy Group. Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. A randomized, single-blind, multicenter clinical trial. N Engl J Med 1991;324:1779-84
37. Chen C, Chang TT. Prophylactic endoscopic variceal ligation (EVL) for esophageal varices [abstract]. Gastroenterology 1997;112:A1240
38. Gameel K, Waked I, Saleh S, et al. Prophylactic endoscopic variceal band ligation (EVL) versus sclerotherapy (ES) for the prevention of variceal bleeding: an interim report of a prospective randomized controlled trial in schistosomal portal hypertension [abstract]. Hepatology 1995;22:251A
39. Lay CS, Tsai YT, Teg CY, et al. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology 1997;25:1346-50
40. Lo GH, Lai KH, Cheng JS, et al. Prophylactic banding ligation of high-risk esophageal varices in patients with cirrhosis: a prospective, randomized trial. J Hepatol 1999;31:451-6
41. Omar MM, Attia MH, Mostafa IM. Prophylactic band ligation to prevent first bleeding from large esophageal varices [abstract]. Gastrointest Endosc 2000;51:AB122
42. Sarin SK, Guptan RK, Jain AK, Sundaram KR. A randomized controlled trial of endoscopic variceal band ligation for primary prophylaxis of variceal bleeding. Eur J Gastroenterol Hepatol 1996;8:337-42 (Pubitemid 26171219)
43. Triantos C, Vlachogiannakos J, Armonis A, et al. Primary prophylaxis of variceal bleeding in cirrhotics unable to take blockers: a randomized trial of ligation. Aliment Pharmacol Ther 2005;21:1435-43 (Pubitemid 40874160)
44. Schepke M, Kleber G, Nurnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004;40:65-72 (Pubitemid 38868924)
45. Triantos C, Vlachogiannakos J, Manolakopoulos S, et al. Is banding ligation for primary prevention of variceal bleeding as effective as beta-blockers, and is it safe? Hepatology 2006;43:196-7 (Pubitemid 43733610)
46. Chen C, Sheu M, Su S. Prophylactic endoscopic variceal ligation (EVL) with multiple band ligator for esophageal varices [abstract]. Gastroenterology 1998;144:A1224
47. De la Mora J, Farca-Belsaguy A, Uribe M, De Hoyos-Garza A. Ligation vs propranolol for primary prophylaxis of variceal bleeding using a multiple band ligator and objective measurements of treatment adequacy: preliminary results [abstract]. Gastroenterology 2000;1118:6512
48. De BK, Ghoshal UC, Das T, et al. Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial. J Gastroenterol Hepatol 1999;14:220-4 (Pubitemid 29166598)
49. Drastich P, Lata J, Petryl J, et al. Endoscopic variceal band ligation in comparison with propranolol in prophylaxis of first variceal bleeding in patients with liver cirrhosis [abstract]. J Hepatol 2005;42(suppl 2):79
50. Gheorge C, Gheorge L, Vadan R, et al. Prophylactic banding ligation of high risk esophageal varices in patients on the waiting list for liver transplantation: an interim report [abstract]. J Hepatol 2002;36(suppl 1):38
51. Jutabha R, Jensen DM, Martin P, et al. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 2005;128:870-81 (Pubitemid 40523540)
52. Lo GH, Chen WC, Chen MH, et al. Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 2004;59:333-8
53. Lui HF, Stanley AJ, Forrest EH, et al. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 2002;123:735-44 (Pubitemid 34977080)
54. Norberto L, Polese L, Cillo U, et al. A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl 2007;13:1272-8 (Pubitemid 47457054)
55. Psilopoulos D, Galanis P, Goulas S, et al. Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial. Eur J Gastroenterol Hepatol 2005;17:1111-17 (Pubitemid 41424006)
56. Sarin SK, Lamba GS, Kumar M, et al. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999;340:988-93 (Pubitemid 29157630)
57. Song I, Shin J, Kim I, et al. A prospective randomized trial between the prophylactic endoscopic variceal ligation and propranolol administration for prevention of first bleeding in cirrhotic patients with high risk esophageal varices [abstract]. J Hepatol 2000;32(suppl 2):41
58. Thuluvath PJ, Maheshwari A, Jagannath S, Arepally A. A randomized controlled trial of beta-blockers versus endoscopic band ligation for primary prophylaxis: a large sample size is required to show a difference in bleeding rates. Dig Dis Sci 2005;50:407-10 (Pubitemid 40311556)
59. Abdelfattah M, Rased M, Elfakhry A, et al. Endoscopic variceal ligation versus pharmacologic treatment for primary prophylaxis of variceal bleeding: a randomised trial. J Hepatol 2006;44:S83
60. Wang HM, Lo GH, Chen WC, et al. Comparison of endoscopic variceal ligation and nadolol plus isosorbide-5-mononitrate in the prevention of first variceal bleeding in cirrhotic patients. J Chin Med Assoc 2006;69:453-60
61. Burroughs AK. Primary prevention of variceal haemorrhage: a pharmacological approach. J Hepatol 2010;52(6):946-8
62. Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009;50:825-33
63. Tsochatzis EA, Triantos CK, Burroughs AK. Gastrointestinal bleeding: carvedilol-the best beta-blocker for primary prophylaxis? Nat Rev Gastroenterol Hepatol 2009;6:692-4
64. Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 2010;51:2214-18
65. Lo GH, Chen WC, Wang HM, Lee CC. Controlled trial of ligation plus nadolol versus nadolol alone for the prevention of first variceal bleeding. Hepatology 2010;52:230-7
66. Gotoh Y, Iwakiri R, Sakata Y, et al. Evaluation of endoscopic variceal ligation in prophylactic therapy for bleeding of oesophageal varices: a prospective, controlled trial compared with endoscopic injection sclerotherapy. J Gastroenterol Hepatol 1999;14:241-4 (Pubitemid 29166602)
67. Svoboda P, Kantorova I, Ochmann J, et al. A prospective randomized controlled trial of sclerotherapy vs ligation in the prophylactic treatment of high-risk esophageal varices. Surg Endosc 1999;13:580-4 (Pubitemid 29277228)
68. Conn HO, Lindenmuth WW. Prophylactic portacaval anastomosis in cirrhotic patients with esophageal varices: a progress report of a continuing study. N Engl J Med 1965;272:1255-63
69. Conn HO, Lindenmuth WW, May CJ, Ramsby GR Prophylactic portacaval anastomosis. Medicine (Baltimore) 1972;51:27-40
70. Jackson FC, Perrin EB, Smith AG, et al. A clinical investigation of the portacaval shunt. II. Survival analysis of the prophylactic operation. Am J Surg 1968;115:22-42
71. Resnick RH, Chalmers TC, Ishihara AM, et al. A controlled study of the prophylactic portacaval shunt. A final report. Ann Intern Med 1969;70:675-88
72. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332-54
73. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-76 (Pubitemid 40805288)
74. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922-38 (Pubitemid 47436138)
75. Bernard B, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997;25:63-70 (Pubitemid 27014986)
76. Thalheimer U, Leandro G, Samonakis DN, et al. Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patients. Dig Liver Dis 2005;37:601-8 (Pubitemid 44356073)
77. Perello A, Escorsell A, Bru C, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology 1999;30:1393-7
78. Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis ofcirrhosis. Hepatology 2003;37:902-8 (Pubitemid 36397403)
79. Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet 2003;361:952-4 (Pubitemid 36332114)
80. Thalheimer U, Mela M, Patch D, Burroughs AK. Prevention of variceal rebleeding. Lancet 2003;361:2244-5
81. Thalheimer U, Mela M, Patch D, Burroughs AK. Targeting portal pressure measurements: a critical reappraisal. Hepatology 2004;39:286-90 (Pubitemid 38222166)
82. Thalheimer U, Mela M, Patch D, Burroughs AK. Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence. Gut 2004;53:143-8 (Pubitemid 38083023)
83. Thalheimer U, Leandro G, Mela M, et al. Systematic review of HVPG measurement: statistics versus clinical applicability. Gastroenterology 2007;132:1201-2 (Pubitemid 46440899)
84. DAmico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006;131:1611-24 (Pubitemid 44708947)
85. DAmico G, Luca A, Garcia-Pagan JC, Bosch J. Author reply. Gastroenterology 2007;132:1202-4
86. Albillos A, Banares R, Gonzalez M, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 2007;102:1116-26 (Pubitemid 46698256)
87. Thalheimer U, Bosch J, Burroughs AK. How to prevent varices from bleeding: shades of grey-the case for nonselective beta blockers. Gastroenterology 2007;133:2029-36 (Pubitemid 350180826)
88. Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991;114:869-73
89. Gonzalez-Abraldes J, Albillos A, Banares R, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001;121:382-8 (Pubitemid 32729385)
90. Albillos A, Garcia-Pagan JC, Iborra J, et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 1998;115:116-23 (Pubitemid 28307295)
91. Abecasis R, Kravetz D, Fassio E, et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study. Hepatology 2003;37:359-65 (Pubitemid 36152535)
92. Gournay J, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000;31:1239-45 (Pubitemid 30351284)
93. Patti R, D'Amico G, Pasta H, et al. Isosorbite mononitrate with nadolol compared to nadolol alone for prevention of recurrent bleeding in cirrhosis. Double-blind placebo controlled randomized trial [abstract]. J Hepatol 1999;30:81
94. Sclerotherapy after first variceal hemorrhage in cirrhosis. A randomized multicenter trial. The Copenhagen Esophageal Varices Sclerotherapy Project. N Engl J Med 1984;311:1594-600
95. Burroughs AK, McCormick PA, Siringo S, et al. Prospective randomized trial of long term sclerotherapy for variceal rebleeding, using the same protocol to treat rebleeding in all patients. Final report [abstract]. J Hepatol 1989;9:S12
96. Korula J, Yellin A, Yamada S, et al. A prospective randomized controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's class a cirrhotics [abstract]. Hepatology 1988;8:1242
97. Rossi V, Cales P, Burtin P, et al. Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy. J Hepatol 1991;12:283-9
98. Soderlund C, Ihre T. Endoscopic sclerotherapy v. conservative management of bleeding oesophageal varices. A 5-year prospective controlled trial of emergency and long-term treatment. Acta Chir Scand 1985;151:449-56 (Pubitemid 16229569)
99. Terblanche J, Bornman PC, Kahn D, et al. Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal variceal bleeding. A five-year prospective controlled clinical trial. Lancet 1983;2:1328-32 (Pubitemid 14245027)
100. Westaby D, Macdougall BR, Williams R. Improved survival following injection sclerotherapy for esophageal varices: final analysis of a controlled trial. Hepatology 1985;5:827-30 (Pubitemid 15236629)
101. Triantos C, Goulis J, Burroughs AK. Portal hypertensive bleeding. Evidence-based gastroenterology and hepatology. 3rd edition. Oxford: Blackwell; 2010. p. 562-602
102. Avgerinos A, Armonis A, Manolakopoulos S, et al. Endoscopic sclerotherapy versus variceal ligation in the long-term management of patients with cirrhosis after variceal bleeding. A prospective randomized study. J Hepatol 1997;26:1034-41 (Pubitemid 27242593)
103. Baroncini D, Milandri GL, Borioni D, et al. A prospective randomized trial of sclerotherapy versus ligation in the elective treatment of bleeding esophageal varices. Endoscopy 1997;29:235-40 (Pubitemid 27322924)
104. Gimson AE, Ramage JK, Panos MZ, et al. Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices. Lancet 1993;342:391-4 (Pubitemid 23236351)
105. Hou MC, Lin HC, Kuo BI, et al. Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: a prospective randomized trial. Hepatology 1995;21:1517-22
106. Jensen DM, Kovacs T, Randall GM, et al. Initial results of a randomized prospective study of emergency banding vs sclerotherapy for bleeding gastric or esophageal varices [abstract]. Gastrointest Endosc 1993;39:128A
107. Jensen DM, Kovacs T, Jutabha R, et al. Randomized, blinded prospective study of banding vs. sclerotherapy for preventing recurrent variceal hemorrhage for patients without active bleeding at endoscopy [abstract]. Gastrointest Endosc 1995;41:315A
108. Laine L, el Newihi HM, Migikovsky B, et al. Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med 1993;119:1-7 (Pubitemid 23177290)
109. Lo GH, Lai KH, Cheng JS, et al. A prospective, randomized trial of sclerotherapy versus ligation in the management of bleeding esophageal varices. Hepatology 1995;22:466-71
110. Lo GH, Lai KH, Cheng JS, et al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology 1997;25:1101-4
111. Masci E, Norberto L, D'Imperio N, et al. Prospective multicentric randomized trial comparing banding ligation with sclerotherapy of esophageal varices [abstract]. Gastrointest Endosc 1997;45:847A
112. Mundo F, Mitrani C, Rodriguez G, Farca A. Endoscopic variceal treatment, is band ligation taking over sclerotherapy? [abstract]. Am J Gastroenterol 1993;88:1493A
113. Stiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992;326:1527-32
114. Young MF, Sanowski RA, Rasche R Comparison and characterization of ulcerations induced by endoscopic ligation of esophageal varices versus endoscopic sclerotherapy. Gastrointest Endosc 1993;39:119-22 (Pubitemid 23139700)
115. Jain AK, Ray RP, Gupta J. Management of acute variceal bleed: randomized trial of variceal ligation and sclerotherapy [abstract]. Hepatology 1996;23:I-51
116. Mostafa I, Omar M, Fakhry S, et al. Prospective randomized comparative study of injection sclerotherapy and band ligation for bleeding esophageal varices [abstract]. Hepatology 1996;23:I-63
117. Salem S, Shiha G. A prospective randomized trial of sclerotherapy versus saeed six-shooter multiband ligation in the control of acute bleeding from oesophageal varices [abstract]. Gut 1999;44(Suppl 1):A19
118. Sarin SK, Govil A, Jain AK, et al. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997;26:826-32 (Pubitemid 27145705)
119. Shafqat F, Khan AA, Alam A, et al. Band ligation vs endoscopic sclerotherapy in esophageal varices: a prospective randomized comparison. J Pak Med Assoc 1998;48:192-6 (Pubitemid 128706635)
120. Shiha GE, Farag FM. Endoscopic variceal ligation versus endoscopic sclerotherapy for the management of bleeding varices [abstract]. Hepatology 1997;26:136A
121. Fakhry S, Omar M, Mustafa A, et al. Endoscopic sclerotherapy versus endoscopic variceal ligation in the management of bleeding esophageal varices: a final report of a prospective randomized study in schistosomal heaptic fibrosis [abstract]. Hepatology 1997;26:137A
122. Agrawall SR, Gupta R, Marthy NS, et al. Comparable efficacy of propranolol plus isosorbide monitrate and endoscopic variceal ligation in prevention of variceal rebleed [abstract]. J Hepatol 2002;36:631A
123. Lo GH, Chen WC, Lin CK, et al. Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding. Hepatology 2008;48:580-7
124. Minyana J, Gallego A, Sola V, et al. Endoscopic ligation versus nadolol plus isosorbide-5-mononitrate for the prevention of variceal rebleeding. A prospective and randomized trial. Hepatology 1999;30:214A
125. Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002;123:1013-19
126. Romero G, Kravetz D, Argonz J, et al. Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial. Aliment Pharmacol Ther 2006;24:601-11 (Pubitemid 44127841)
127. Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001;345:647-55
128. Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 2000;32:461-5
129. de la PJ, Brullet E, Sanchez-Hernandez E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005;41:572-8 (Pubitemid 40289505)
130. Garcia-Pagan JC, Villanueva C, Albillos A, et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut 2009;58:1144-50
131. Villanueva C, Aracil C, Colomo A, et al. Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy. Aliment Pharmacol Ther 2009;29:397-408
132. Escorsell A, Banares R, Garcia-Pagan JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002;35:385-92 (Pubitemid 34106379)
133. Cabrera J, Maynar M, Granados R, et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996;110:832-9 (Pubitemid 26075449)
134. Cello JP, Ring EJ, Olcott EW, et al. Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. A randomized, controlled trial. Ann Intern Med 1997;126:858-65
135. Garcia-Villarreal L, Martinez-Lagares F, Sierra A, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage. Hepatology 1999;29:27-32 (Pubitemid 29023981)
136. Groupe d Etude des Anastomoses Intrahepatiques. TIPS vs sclerotherapy plus propranolol in the prevention of variceal rebleeding-preliminary results of a multicenter randomized trial [abstract]. Hepatology 1995; 22: 761
137. Merli M, Salerno F, Riggio O, et al.; Gruppo Italiano Studio TIPS (GIST). Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Hepatology 1998;27:48-53 (Pubitemid 28041533)
138. Narahara Y, Kanazawa H, Kawamata H, et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatol Res 2001;21:189-98 (Pubitemid 33061716)
139. Rossle M, Deibert P, Haag K, et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997;349:1043-9 (Pubitemid 27158248)
140. Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996;111:138-46 (Pubitemid 26226893)
141. Sauer P, Theilmann L, Stremmel W, et al. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology 1997;113:1623-31 (Pubitemid 27461249)
142. Gulberg V, Schepke M, Geigenberger G, et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scand J Gastroenterol 2002;37:338-43 (Pubitemid 34194821)
143. Jalan R, Forrest EH, Stanley AJ, et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology 1997;26:1115-22 (Pubitemid 27509291)
144. Pomier-Layrargues G, Dufresne MP, Bui B, et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interim analysis) [abstract]. Hepatology 1997;26:3
145. Sauer P, Hansmann J, Richter GM, et al. Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy 2002;34:690-7 (Pubitemid 34965668)
146. Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998;114:1296-303 (Pubitemid 28243916)
147. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004;126:469-75 (Pubitemid 38182304)
148. Fernandez-Aguilar JL, Bondia Navarro JA, Santoyo SJ, et al. Calibrated portacaval H-graft shunt in variceal hemorrhage. Long-term results. Hepatogastroenterology 2003;50:2000-4 (Pubitemid 37467981)
149. Orozco H, Mercado MA, Chan C, et al. A comparative study of the elective treatment of variceal hemorrhage with beta-blockers, transendoscopic sclerotherapy, and surgery: a prospective, controlled, and randomized trial during 10 years. Ann Surg 2000;232:216-19 (Pubitemid 30616722)
150. Khaitiyar JS, Luthra SK, Prasad N, et al. Transjugular intrahepatic portosystemic shunt versus distal splenorenal shunt-a comparative study. Hepatogastroenterology 2000;47:492-7 (Pubitemid 30216321)
151. Rosemurgy AS, Goode SE, Zwiebel BR, et al. A prospective trial of transjugular intrahepatic portasystemic stent shunts versus small-diameter prosthetic H-graft portacaval shunts in the treatment of bleeding varices. Ann Surg 1996;224:378-84
152. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-8
153. Bernard B, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29:1655-61 (Pubitemid 29247035)
154. Soares-Weiser K, Brezis M, Tur-Kaspa R, et al. Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis of randomized controlled trials. Scand J Gastroenterol 2003;38:193-200 (Pubitemid 36349932)
155. Imperiale TF, Teran JC, McCullough AJ. A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology 1995;109:1289-94
156. Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004;39:746-53
157. Fernandez J, Ruiz del AL, Gomez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006;131:1049-56 (Pubitemid 44498687)
158. Sonnenberg GE, Keller U, Perruchoud A, et al. Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects. Gastroenterology 1981;80:526-32 (Pubitemid 11183954)
159. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 1981;80:518-25 (Pubitemid 11183953)
160. Jenkins SA, Baxter JN, Corbett WA, Shields R. Effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the pig and on intravariceal pressure in man. Br J Surg 1985;72:1009-12 (Pubitemid 16179281)
161. McCormick PA, Biagini MR, Dick R, et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. Hepatology 1992;16:1180-6
162. Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001;120:161-9 (Pubitemid 32061880)
163. Freeman JG, Cobden I, Record CO. Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding. J Clin Gastroenterol 1989;11:58-60 (Pubitemid 19060146)
164. Levacher S, Letoumelin P, Pateron D, et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995;346:865-8
165. Patch D, Caplin M, Greenslade L, Burroughs A. Randomized double blind controlled trial of 5 day terlipressin vs placebo in acute variceal hemorrhage [abstract]. J Hepatol 1999;30:55
166. Pauwels A, Florent C, Desaint B, et al. Terlipressin and somatostatin in the treatment of hemorrhages from rupture of esophageal varices. Gastroenterol Clin Biol 1994;18:388-9 (Pubitemid 24207269)
167. Soderlund C, Magnusson I, Torngren S, Lundell L. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 1990;25:622-30 (Pubitemid 20186798)
168. Walker S, Stiehl A, Raedsch R, Kommerell B. Terlipressin in bleeding esophageal varices: a placebo-controlled, double-blind study. Hepatology 1986;6:112-15 (Pubitemid 16137853)
169. Burroughs AK, McCormick PA, Hughes MD, et al. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. Gastroenterology 1990;99:1388-95 (Pubitemid 20381875)
170. Gotzsche PC, Gjorup I, Bonnen H, et al. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ 1995;310:1495-8
171. Valenzuela JE, Schubert T, Fogel MR, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989;10:958-61 (Pubitemid 20341083)
172. Moitinho E, Planas R, Banares R, et al. Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001;35:712-18 (Pubitemid 34717661)
173. Chelarescu D, Gabor O, Lunca C. Terlipressin vs somatostatin in acute variceal bleeding: a prospective, randomized trial. J Hepatol 2001;34(Suppl 1):78
174. Feu F, Ruiz DA, Banares R, et al.; Variceal Bleeding Study Group. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Gastroenterology 1996;111:1291-9 (Pubitemid 26362254)
175. Walker S, Kreichgauer HP, Bode JC. Terlipressin (glypressin) versus somatostatin in the treatment of bleeding esophageal varices-final report of a placebo-controlled, double-blind study. Z Gastroenterol 1996;34:692-8 (Pubitemid 26348010)
176. Burroughs A; International Octreotide Varices Study Group. Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial failures [abstract]. Hepatology 1996;24:352A
177. D'Amico G, Politi F, Morabito A, et al. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. Hepatology 1998;28:1206-14 (Pubitemid 28493829)
178. Primignani M, Andreoni B, Carpinelli L, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial. New Italian Endoscopic Club. Hepatology 1995;21:1322-7
179. Hubmann R, Bodlaj G, Czompo M, et al. The use of self-expanding metal stents to treat acute esophageal variceal bleeding. Endoscopy 2006;38:896-901 (Pubitemid 44430687)
180. Burroughs AK, Triantos CK. Predicting failure to control bleeding and mortality in acute variceal bleeding. J Hepatol 2008;48:185-8
181. Bosch J, Thabut D, Albillos A, et al. Recombinant factor VIIA (RFVIIA) for active variceal bleeding in patients with advanced cirrhosis: a multi-centre randomized double-blind placebo-controlled trial. J Hepatol 2007;46(Suppl 1):295
182. Bosch J, Thabut D, Albillos A, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 2008;47:1604-14 (Pubitemid 351702743)
183. Hartigan PM, Gebhard RL, Gregory PB.; Veterans Affairs Cooperative Variceal Sclerotherapy Group. Sclerotherapy for actively bleeding esophageal varices in male alcoholics with cirrhosis. Gastrointest Endosc 1997;46:1-7 (Pubitemid 27430354)
184. Villanueva C, Piqueras M, Aracil C, et al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol 2006;45:560-7 (Pubitemid 44307385)
185. Djurdjevic D, Janosevic S, Dapcevic B, et al. Combined ligation and sclerotherapy versus ligation alone for eradication of bleeding esophageal varices: a randomized and prospective trial. Endoscopy 1999;31:286-90 (Pubitemid 29229365)
186. Vangeli M, Patch D, Burroughs AK. Salvage tips for uncontrolled variceal bleeding. J Hepatol 2002;37:703-4 (Pubitemid 35305558)
187. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004;40:793-801 (Pubitemid 39288111)
188. Garcia-Pagan JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362:2370-9
189. Abraldes JG, Villanueva C, Banares R, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 2008;48:229-36
190. Guerrini GP, Pleguezuelo M, Maimone S, et al. Impact of tips preliver transplantation for the outcome posttransplantation. Am J Transplant 2009;9:192-200
191. Colomo A, Hernandez-Gea V, Madoz P, et al. Hemodynamic changes and transfusion strategies in cirrhotic patients with acute variceal bleeding [abstract]. Hepatology 2009;50(4 Suppl):403A
192. Sarin SK, Lahoti D, Saxena SP, et al. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 1992;16:1343-9
193. Ramond MJ, Valla D, Mosnier JF, et al. Successful endoscopic obturation of gastric varices with butyl cyanoacrylate. Hepatology 1989;10:488-93 (Pubitemid 19255471)
194. Oho K, Iwao T, Sumino M, et al. Ethanolamine oleate versus butyl cyanoacrylate for bleeding gastric varices: a nonrandomized study. Endoscopy 1995;27:349-54
195. Tan PC, Hou MC, Lin HC, et al. A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology 2006;43:690-7
196. Lo GH, Lai KH, Cheng JS, et al. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001;33:1060-4
197. Williams SG, Peters RA, Westaby D. Thrombin-an effective treatment for gastric variceal haemorrhage. Gut 1994;35:1287-9 (Pubitemid 24277346)
198. Chau TN, Patch D, Chan YW, et al. 'Salvage' transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 1998;114:981-7 (Pubitemid 28217564)
199. Cho SK, Shin SW, Lee IH, et al. Balloon-occluded retrograde transvenous obliteration of gastric varices: outcomes and complications in 49 patients. AJR Am J Roentgenol 2007;189:W365-72
200. Ninoi T, Nishida N, Kaminou T, et al. Balloon-occluded retrograde transvenous obliteration of gastric varices with gastrorenal shunt: long-term follow-up in 78 patients. AJR Am J Roentgenol 2005;184:1340-6 (Pubitemid 43821924)
201. Lo GH, Liang HL, Chen WC, et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy 2007;39:679-85
202. Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009;136:1651-8
203. Tandon P, Abraldes JG, Berzigotti A, et al. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol 2010;53:273-82
204. Vlachogiannakos J, Tang AK, Patch D, Burroughs AK. Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. Gut 2001;49:303-8 (Pubitemid 32675127)
205. Mejias M, Garcia-Pras E, Tiani C, et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009;49:1245-56
206. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010;53:762-8
207. Thalheimer U, De Iorio F, Capra F, et al. Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study. Eur J Gastroenterol Hepatol 2010;22(10):1228-34
208. Tsochatzis EA, Triantos CK, Garcovich M, Burroughs AK. Primary prevention of variceal haemorrhage. Curr Gastroenterol Rep 2010; In press
209. Triantos C, Samonakis D, Thalheimer U, et al. The relationship between liver function and portal pressure: what comes first, the chicken or the egg? J Hepatol 2005;42:146-7